GAIN THERAPEUTICS, INC Increase (Decrease) in Accounts Payable and Accrued Liabilities
GAIN THERAPEUTICS, INC (GANX) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $46.66 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-11
- GAIN THERAPEUTICS, INC increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$485.10K, a 419.88% decline year-over-year.
- GAIN THERAPEUTICS, INC increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $531.77K, a 52.27% decline year-over-year.
- GAIN THERAPEUTICS, INC increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$785.26K.
- GAIN THERAPEUTICS, INC increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$949.14K.
- GAIN THERAPEUTICS, INC increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$468.61K, a 270.47% decline from fiscal 2024.
- GAIN THERAPEUTICS, INC increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $274.89K.
- GAIN THERAPEUTICS, INC increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$693.70K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$485.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $46.66K 10-Q · filed 2026-08-11 | -$738.60K derived: sum of 3 quarters · filed 2026-08-11 | -$1.69M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $531.77K 10-Q · filed 2026-05-11 | -$253.49K derived: sum of 2 quarters · filed 2026-05-11 | -$1.20M derived: sum of 3 quarters · filed 2026-05-11 | -$1.05M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | -$785.26K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$1.73M derived: sum of 2 quarters · filed 2026-03-26 | -$1.58M derived: sum of 3 quarters · filed 2026-08-11 | -$468.61K 10-K · filed 2026-03-26 | |
| 2025-09-30 | -$949.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$797.49K derived: sum of 2 quarters · filed 2026-08-11 | $316.65K 10-Q · filed 2025-11-12 | $258.58K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $151.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.27M 10-Q · filed 2026-08-11 | $1.21M derived: sum of 3 quarters · filed 2026-08-11 | -$645.95K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $1.11M 10-Q · filed 2026-05-11 | $1.06M derived: sum of 2 quarters · filed 2026-05-11 | -$797.60K derived: sum of 3 quarters · filed 2026-05-11 | $685.44K derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | -$58.07K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$1.91M derived: sum of 2 quarters · filed 2026-03-26 | -$428.70K derived: sum of 3 quarters · filed 2026-03-26 | $274.89K 10-K · filed 2026-03-26 | |
| 2024-09-30 | -$1.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$370.63K derived: sum of 2 quarters · filed 2025-11-12 | $332.96K 10-Q · filed 2025-11-12 | -$694.36K derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $2.19M 10-Q · filed 2025-08-12 | $1.16M derived: sum of 3 quarters · filed 2025-08-12 | $1.11M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $703.59K 10-Q · filed 2025-05-14 | -$323.73K derived: sum of 2 quarters · filed 2025-05-14 | -$369.83K derived: sum of 3 quarters · filed 2025-05-14 | -$1.05M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | -$1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$1.07M derived: sum of 2 quarters · filed 2025-03-27 | -$1.75M derived: sum of 3 quarters · filed 2025-03-27 | -$693.70K 10-K · filed 2025-03-27 | |
| 2023-09-30 | -$46.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$723.95K derived: sum of 2 quarters · filed 2024-11-14 | $333.62K 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | -$677.85K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $379.72K 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $1.06M 10-Q · filed 2024-05-14 | ||||
| 2022-09-30 | $300.59K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$209.59K derived: sum of 2 quarters · filed 2023-11-14 | $1.53M 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | -$510.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.23M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $1.74M 10-Q · filed 2023-05-12 | ||||
| 2021-09-30 | $1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.17M derived: sum of 2 quarters · filed 2022-11-10 | $1.25M 10-Q · filed 2022-11-10 | $1.25M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $8.13K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $91.06K 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | $82.93K 10-Q · filed 2021-05-10 | ||||
| 2020-09-30 | $156.36K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $311.31K derived: sum of 2 quarters · filed 2021-11-12 | $126.39K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $154.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$29.96K 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | -$184.92K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |